WordNet

any substance or organism that provokes an immune response (produces immunity) when introduced into the body (同)immunizing agent
possessing the ability to elicit an immune response
the property of eliciting an immune response

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/04/10 18:36:49」(JST)

wiki en

An immunogen is an antigen or any substance that may be specifically bound by components of the immune system (antibody, lymphocytes). The term antigen arises from its ability to induce generation of antibodies (antigen = antibody generation). Despite the fact that all antigens are recognized by specific lymphocytes or by antibodies, not every antigen can evoke an immune response. Those antigens that are capable of inducing an immune response are said to be immunogenic and are called immunogens.^[1]

An immunogen is any antigen that is capable of inducing humoral and/or cell-mediated immune response rather than immunological tolerance. This ability is called immunogenicity. Sometimes the term immunogen is used interchangeably with the term antigen. But only an immunogen can evoke an immune response.^[2]

Generally, both are substances that are capable of generating antibodies (antigen) or immune responses (immunogen).

We can define an immunogen as a complete antigen which is composed of the macromolecular carrier and epitopes (determinants) that can induce immune response.^[3]

An explicit example is a hapten. Haptens are low-molecular-weight compounds that may be bound by antibodies, but cannot elicit an immune response. Consequently, the haptens themselves are nonimmunogenic and they cannot evoke an immune response until they bind with a larger carrier immunogenic molecule. The hapten-carrier complex, unlike free hapten, can act as an immunogen and can induce an immune response. ^[4]

Until 1959, the terms immunogen and antigen were not distinguished.^[5]

Used carrier proteins

Keyhole Limpet Hemocyanin (KLH)

It is copper-containing respiratory protein, isolated from keyhole limpets (Megathura crenulata). Because of its evolutionary distance from mammals, high molecular weight and complex structure it is usually immunogenic in vertebrate animals.^[6]

Concholepas Concholepas Hemocyanin (CCH)

(also Blue Carrier Immunogenic Protein) It is alternative to KLH isolated from Concholepas concholepas.It has the similar immunogenic properties as KLH but better solubility and therefore better flexibility.^[7]

Bovine Serum Albumin (BSA)

It is from the blood sera of cows and has similarly immunogenic properties as KLH or CCH. The cationized form of BSA (cBSA) is highly positively charged protein with significantly increased immunogenicity. This change possesses a greater number of possible conjugated antigens to the protein.^[8]

Ovalbumin (OVA)

Also known as egg albumin, the main protein (60-75% ) found in hen egg white. OVA is being soluble in Dimethyl Sulfoxide (DMSO) what enable conjugation of haptens that are not soluble in aqueous buffers. Immune response can be enhanced by using an ajuvant injected together with the immunogen.^[9]

Immunological adjuvants

An adjuvant (from Latin adiuvare – to help) is any substance, distinct from antigen, which enhances immune response by various mechanisms: recruiting of professional antigen-presenting cells (APCs) to the site of antigen exposure; increasing the delivery of antigens by delayed/slow release (depot generation); immunomodulation by cytokine production (selection of Th1 or Th2 response); inducing T-cell response (prolonged exposure of peptide-MHC complexes [signal 1] and stimulation of expression of T-cell-activating co-stimulators [signal 2] on the APCs' surface) and targeting (e. g. carbohydrate adjuvants which target lectin receptors on APCs). Adjuvants have been used as additives to improve vaccine efficiency since the 1920s. Generally, administration of adjuvants is used both in experimental immunology and in clinical settings to ensure a high quality/quantity memory-enhanced antibody response, where antigens must be prepared and delivered in a fashion that maximizes production of a specific immune response. Among commonly used adjuvants are Complete and Incomplete Freund's adjuvant and solutions of aluminum hydroxide or aluminum phosphate.^[10]^[11]

References

^ Murphy K. (2012). Janeway’s Immunobiology 8th edition. Garland Science. pp. 717–721, 789.
^ Cruse J.M., Lewis R.E. (2010). Atlas Of Immunology. CRC Press. p. 167.
^ Cruse J.M., Lewis R.E. (2010). Atlas Of Immunology. CRC Press. p. 163.
^ Abbas A.K., Lichtman A.H., Pillai S. (2012). Cellular and Molecular Immunology. 7th edition. Elsevier, Ed. Gruliow R. pp. 101–103, 483.
^ Medical Dictionary, Merriam-Webster. "Immunogen".
^ Harris J.R., Markl J. (1999). "Keyhole limpet hemocyanin (KHL): a biomedical review". Micron 30 (6): 597–623. doi:10.1016/s0968-4328(99)00036-0.
^ Arancibia S., Del Campo M., Nova E., Salazar F., Becker M.I. (2012). "Enhanced structural stability of Concholepashemocyanin increases its immunogenicity and maintains its non-specific immunostimulatory effects". Eur J Immunol 42 (3): 688–99. doi:10.1002/eji.201142011.
^ Chen J.S., Chen A., Chang L.Ch., Chang W.S.W., Lee H.S., Lin S.H., Lin Y.F. (2004). "Mouse model of membranous nephopathy induced by cationic bovine serum albumin: antigen dose response relation and strain differences". Nephrol Dial Transplantant 19: 2721–2728.
^ De Silva B.S., Egodage K.L., Wilson G.S. (1999). "Purified protein derivate (PPD) as an immunogen carrier elicits high antigen specificity to haptens". Bioconjug Chem 10 (3): 496–501. doi:10.1021/bc9800724.
^ Abbas A.K., Lichtman A.H., Pillai S. (2012). Cellular and Molecular Immunology. Elsevier. p. 85.
^ Cox J.C., Coulter A.R. (1997). "Adjuvants –a classification and review of their modes of action". Vaccine 15 (3): 248–256. doi:10.1016/s0264-410x(96)00183-1.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 去勢抵抗性前立腺癌に対する免疫療法 immunotherapy for castration resistant prostate cancer
2. 成人の腎移植における免疫抑制誘導療法 induction immunosuppressive therapy in renal transplantation in adults
3. D型肝炎ウイルス感染の治療および予防 treatment and prevention of hepatitis d virus infection
4. 再発性多発性軟骨炎の病因および発症機序 etiology and pathogenesis of relapsing polychondritis
5. インフルエンザ菌感染の予防 prevention of haemophilus influenzae infection

English Journal

Six-week follow-up after HIV-1 exposure: a position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy.

Gaines H1,2,3, Albert J4,5,6, Axelsson M1, Berglund T1, Gisslén M6,7, Sönnerborg A3,5,6,8, Blaxhult A9, Bogdanovic G5, Brytting M1, Carlander C6,10, Flamholc L6,11, Follin P12, Haggar A13, Hagstam P14, Johansson M15, Navér L6,16,17, Persson Blom J18, Samuelson A5, Ström H13, Sundqvist M19, Svedhem Johansson V3, Tegmark Wisell K1, Tegnell A1, Thorstensson R1.
Infectious diseases (London, England).Infect Dis (Lond).2016 Feb;48(2):93-8. doi: 10.3109/23744235.2015.1089593. Epub 2015 Sep 28.
In 2014 the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy (RAV) conducted a review and analysis of the state of knowledge on the duration of follow-up after exposure to human immunodeficiency virus (HIV). Up until then a follow-up of 12 weeks after exposure had
PMID 26414596

Bubble-Assisted Ultrasound: Application in Immunotherapy and Vaccination.

Escoffre JM1, Deckers R2, Bos C3, Moonen C2.
Advances in experimental medicine and biology.Adv Exp Med Biol.2016;880:243-61. doi: 10.1007/978-3-319-22536-4_14.
Bubble-assisted ultrasound is a versatile technology with great potential in immunotherapy and vaccination. This technology involves the exposure of immune cells (i.e., dendritic cells, lymphocytes) in-vitro or diseased tissues (i.e., brain, tumor) in-vivo to ultrasound treatment with gas bubbles. B
PMID 26486342

αvβ3 Integrin-Targeted Peptide/Peptidomimetic-Drug Conjugates: In-Depth Analysis of the Linker Technology.

Dal Corso A, Pignataro L, Belvisi L1, Gennari C.
Current topics in medicinal chemistry.Curr Top Med Chem.2016;16(3):314-29.
Covalent conjugation of anticancer drugs to targeting carriers (e.g., antibodies or small molecules) capable of selectively binding to tumor-specific antigens, is emerging as a successful strategy to overcome the drawbacks of traditional chemotherapy. Due to its overexpression on blood vessels of hu
PMID 26126915

Japanese Journal

特異体質性薬物毒性の発現メカニズムに関する最近の知見

池田敏彦
薬学雑誌. 乙号 135(4), 567-578, 2015
… Although the mechanism remains unclear, immune reactions are likely involved in the toxic processes underlying idiosyncratic drug toxicity: the drug is first activated into a chemically reactive metabolite that binds covalently to proteins and then acts as an immunogen. …
NAID 130005060823

Passive immunity with multi-serotype heat-killed Shigellae in neonatal mice

Barman Soumik,Koley Hemanta,Nag Dhrubajyoti [他]
Microbiology and immunology 58(8), 463–466, 2014-08
NAID 40020164505

Exogenous Leptin Administered Intramuscularly Induces Sex Hormone Disorder and Ca Loss via Downregulation of Gnrh and PI3K Expression

Wu Lihong,LIU Wen,BAYAER Nashun,GU Weiwang,SONG Jieli
Experimental Animals 63(4), 447-457, 2014
… Thirty female Sprague-Dawley (SD) rats (40 days old) were injected thrice intramuscularly with LEP or keyhole limpet hemocyanin immunogen. … Rats injected with LEP immunogen displayed significantly increased body weight, food intake, Lee's index, serum LEP, serum cortisol, fat deposition in the abdomen, and decreased hormones including follicle stimulating hormone, luteinizing hormone, estradiol, cholecystokinin, and Ca. …
NAID 130005089323